Cost-effectiveness analysis of nilotinib versus imatinib for the treatment of chronic phase philadelphia chromosome positive chronic myeloid leukaemia

Mildred, M., Ward, S., Squires, H. and Gray, E. (2012) Cost-effectiveness analysis of nilotinib versus imatinib for the treatment of chronic phase philadelphia chromosome positive chronic myeloid leukaemia. In: 17th Congress of EHA, 14-17 June 2012, Amsterdam, The Netherlands.

Abstract

Metadata

Authors/Creators:
  • Mildred, M.
  • Ward, S.
  • Squires, H.
  • Gray, E.
Keywords: Antineoplastic Agents; Clinical Trials; Cost-Benefit Analysis; Drug Costs; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Markov Chains; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Survival Analysis
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Health Economics and Decision Science
The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield)
Funding Information:
FunderGrant number
Novartis Pharmaceuticals UK LtdUNSPECIFIED
Depositing User: Mr Matthew Mildred
Date Deposited: 18 May 2012 10:03
Last Modified: 04 Jun 2014 18:55
Status: Published
Refereed: Yes

Download

Filename: Mildred_2012_EHA_poster.pdf

Share / Export